Page last updated: 2024-12-04

2-aminofluorene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1539
CHEMBL ID84472
SCHEMBL ID225901
SCHEMBL ID4185603
MeSH IDM0059062

Synonyms (71)

Synonym
AC-4871
CHEMBL84472
2-aminoflurene
EN300-17389
BB 0221267
9h-fluoren-2-yl-amine
nsc26328
nsc-26328
SGCUT00125
smr000219736
9h-fluoren-2-ylamine
MLS000589201
EU-0034581
OPREA1_099026
aminofluoren [german]
nsc 12274
ccris 31
2-fluroenylamine
hsdb 4026
brn 1945861
einecs 205-817-8
fluoren-2-ylamine
2-fluorenamine
nsc12274
nsc-12274
2-fluorenylamine
aminofluoren
fluoren-2-amine
9h-fluoren-2-amine
wln: l b656 hhj ez
2-aminofluorene
2-fluoreneamine
153-78-6
fluorene, 2-amino-
STK093094
inchi=1/c13h11n/c14-11-5-6-13-10(8-11)7-9-3-1-2-4-12(9)13/h1-6,8h,7,14h
2-aminofluorene, 98%
TO_000026
NCI60_000536
A0621
AKOS000111311
HMS1608K17
NCGC00246308-01
HMS2538L16
unii-3a69os195n
3a69os195n ,
dtxsid1049223 ,
cas-153-78-6
tox21_202971
dtxcid3029079
NCGC00260517-01
BP-12358
FT-0622283
2-aminofluorene [hsdb]
aminofluorene, 2-
SCHEMBL225901
SCHEMBL4185603
Q-101156
F0037-4040
sr-01000398070
SR-01000398070-1
mfcd00001125
SY049251
Q26840753
AS-14460
D70520
2-amino-9h-fluorene
HY-W016433
CS-W017149
2-amino fluorene
PD196987

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" mPDA with or without plant activation was not toxic to the exposed cells."( Genotoxicity of m-phenylenediamine and 2-aminofluorene in Salmonella typhimurium and human lymphocytes with and without plant activation.
Anderson, D; Plewa, MJ; Wagner, ED; Yu, TW, 1995
)
0.56
" Since the dose rate of aromatic amines, like AAF, in feeding studies for tumor formation is about 100 times below that examined in the isolated perfused livers, it is highly unlikely that oxidative stress is generated by metabolites able to undergo redox cycling and that reactive oxygen contributes to acute toxic effects."( Cytotoxicity of aromatic amines in rat liver and oxidative stress.
Hillesheim, W; Jaeschke, H; Neumann, HG, 1995
)
0.29
"Age-related changes in the expression of xenobiotic biotransformation enzymes can result in differences in the rates of chemical activation and detoxification, affecting responses to the therapeutic and/or toxic effects of chemicals."( Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity.
Chau, B; McQueen, CA, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" In dose-response studies in which the concentrations of AF, AcCoA or S9 protein were varied, higher numbers of revertants were consistently generated with hepatic S9 derived from the slow acetylator compared to the rapid acetylator hamsters."( Relationship of Syrian inbred hamster acetylator genotype to the mutagenic activation of 2-aminofluorene.
Andrews, AF; Ferguson, RJ; Heflich, RH; Hein, DW; Kirlin, WG; Minor, TY; Ogolla, F; Trinidad, A; Yerokun, T, 1990
)
0.5
" In this paper we report on an automated system that successfully generates dose-response data and, moreover, reduces the labor, materials, and sample mass required to obtain such information."( Development and validation of the spiral Salmonella assay: an automated approach to bacterial mutagenicity testing.
Claxton, LD; Houk, VS; Schalkowsky, S, 1989
)
0.28
" However, a gene dose-response relationship was observed in the same animals for cytosolic acetyl coenzyme A-dependent 2-aminofluorene N-acetyltransferase activity."( The role of acetylator genotype on hepatic and extrahepatic acetylation, deacetylation, and sulfation of 2-aminofluorene, 2-acetylaminofluorene, and N-hydroxy-2-acetylaminofluorene in the inbred hamster.
Ferguson, RJ; Hein, DW; Kirlin, WG; Ogolla, F; Thompson, LK; Trinidad, A,
)
0.55
" Dose-response parameters for the activation of DMBA by S9 fraction from woodchucks and rats were compared with TA100."( In vitro activation assays with hepatic S9 preparation from wild and laboratory reared woodchucks in the Salmonella mutagenicity test.
Babish, JG; Mumma, RO; Rashid, KA, 1988
)
0.27
" Differences in dose-response curves for certain mutagens using liver and intestinal microsomes are discussed in relation to variation in metabolism of promutagens."( Characterization of a microsomal fraction from rat small intestine for metabolic activation of some promutagens.
Combes, RD; Walters, JM, 1985
)
0.27
"The O-dealkylation of pentoxyresorufin, a substrate for P450 2B1, was decreased in lung microsomes from rats dosed with O,O,S-trimethylphosphorodithioate, O,O,O-trimethylphosphorothioate, bromophos, fenitrothion, p-xylene and 2,4-dichloro-(6-phenylphonoxy)ethylamine."( Inhibition and induction of cytochrome P450 isoenzymes in rat lung.
Dinsdale, D; Verschoyle, RD; Wolf, CR, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.56230.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency100.00000.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency12.58930.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency31.81060.007215.758889.3584AID1224835; AID588342
ClpPBacillus subtilisPotency11.22021.995322.673039.8107AID651965
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.49970.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency11.58210.004110.890331.5287AID504467
GLI family zinc finger 3Homo sapiens (human)Potency2.56640.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency9.98750.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency30.34250.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743036; AID743040; AID743042; AID743054; AID743063
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency15.84890.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency32.16880.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency6.07580.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency27.38420.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency7.24060.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.20320.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency27.13950.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.34330.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743079; AID743080; AID743091
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency45.28620.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.30130.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency100.16300.039147.5451146.8240AID1224845
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.98110.01262.451825.0177AID485313
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency44.66840.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency70.79460.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency3.54810.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency43.01320.000627.21521,122.0200AID743219
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.19950.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.30130.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.30130.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency52.15000.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency54.15040.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
large T antigenBetapolyomavirus macacaeIC50 (µMol)3.52000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID661624Mutagenic activity in Salmonella typhimurium TA 98 assessed as increase in revertants at 20 ug/plate after 48 hrs by Ames test in presence of S9 liver fraction relative to control2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, study on anti-arthritic, anti-inflammatory activity and toxicity of some novel bis-oxy cyclophane diamides.
AID168094Compound was tested for carcinogenic activity on liver after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID307625Partition coefficient, log P of the compound
AID168252Compound was tested for carcinogenic activity on other sites after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168081Compound was tested for carcinogenic activity on ear duct after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168106Compound was tested for carcinogenic activity on mixed data after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID160321Competition for [3H]benzo[a]pyrene-binding site of polycyclic aromatic hydrocarbon binding protein (PBP) from mouse liver1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Voronoi binding site model of a polycyclic aromatic hydrocarbon binding protein.
AID167946Compound was tested for carcinogenic activity on breast after various routes administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID661626Mutagenic activity in Salmonella typhimurium TA 100 assessed as increase in revertants at 20 ug/plate after 48 hrs by Ames test in presence of S9 liver fraction relative to control2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, study on anti-arthritic, anti-inflammatory activity and toxicity of some novel bis-oxy cyclophane diamides.
AID307626Solubility in water
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID168253Compound was tested for carcinogenic various routes subcutaneous administration of the compound; + denotes carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID732978Mutagenicity in Salmonella typhimurium TA98 at 10 ug/plate in presence of S9 fraction2013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1179427Genotoxicity in Salmonella typhimurium TA102 at 1.25 ug/plate assessed as number of revertants per plate in presence of S9 liver extract (Rvb = 327.8 +/- 9.1 no unit)2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (385)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990150 (38.96)18.7374
1990's133 (34.55)18.2507
2000's72 (18.70)29.6817
2010's26 (6.75)24.3611
2020's4 (1.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.62 (24.57)
Research Supply Index6.08 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index32.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (1.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other429 (98.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]